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http://dx.doi.org/10.1016/j.jacl.2014.0BACKGROUND: Mipomersen is an antisense oligonucleotide that inhibits apolipoprotein B synthe-
sis and lowers plasma low-density lipoprotein cholesterol even in the absence of low-density lipopro-
tein receptor function, presumably from inhibition of hepatic production of triglyceride-rich very
low-density lipoprotein particles. By virtue of this mechanism, mipomersen therapy commonly results
in the development of hepatic steatosis. Because this is frequently accompanied by alanine aminotrans-
ferase elevations, concern has arisen that mipomersen could promote the development of steatohepa-
titis, which could in turn lead to fibrosis and cirrhosis over time.
OBJECTIVE: The objective of this study was to assess the liver biopsy findings in patients treated
with mipomersen.
METHODS: We describe 7 patients who underwent liver biopsy during the mipomersen clinical
development programs. Liver biopsies were reviewed by a single, blinded pathologist.
RESULTS: The histopathological features were characterized by simple steatosis, without signifi-
cant inflammation or fibrosis.
CONCLUSION: These findings suggest that hepatic steatosis resulting from mipomersen is distinct
from nonalcoholic steatohepatitis.
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Open access under CC BY-NC-NDMipomersen is an antisense oligonucleotide that inhibits
apolipoprotein B (apoB) synthesis by complexing with the
apoB messenger RNA and leading to cleavage by ribonu-
clease H.1 The reduction of apoB messenger RNA synthesis
appears to decrease the rate of triglyceride-rich very
low-density lipoprotein (VLDL) production. This leads to
reductions in plasma total cholesterol, low-density lipopro-
tein (LDL)-cholesterol, non–high-density lipoprotein
cholesterol, apoB, and lipoprotein(a).2 Importantly, mipo-
mersen lowers plasma LDL-cholesterol concentrations in
hypercholesterolemic patients who are being treated with license.
Hashemi et al Liver histology during Mipomersen therapy 607maximally tolerated lipid-lowering therapy, including those
with homozygous and heterozygous familial hypercholes-
terolemia (FH).3-8
Because the secretion of VLDL particles is integral to
maintaining triglyceride balance within the liver, hepatic
steatosis represents a potential mechanism-based conse-
quence of mipomersen therapy.4 In keeping with this possi-
bility, mipomersen-associated increases in hepatic
triglycerides have been quantified using magnetic reso-
nance imaging (MRI) or spectroscopy (MRS), with liver
fat contents that are inversely correlated with reductions
in plasma apoB-100 concentrations.3,4 When observed in
association with increased transaminase levels, this raised
the concern that mipomersen therapy may lead to liver
changes similar to nonalcoholic steatohepatitis (NASH),
which carries a significant risk of progression to cirrhosis.
Here we report the clinical and histological features of
patients undergoing mipomersen therapy.Methods
In the phase 2 and 3 clinical development and open-label
extension programs for mipomersen, 7 patients underwent
liver biopsy as a component of their clinical care and at the
discretion of the physician. To standardize the histopatho-
logic findings, all biopsy slides were reviewed by a single
experienced hepatopathologist (R.D.O.), who was not affil-
iated with any of the study centers. We note that the biopsies
for cases 1 and 2 were previously reported,4 but these were
reevaluated with the 5 additional biopsies that were
performed in our current mipomersen-treated patients. To
complement case histories, Table 1 summarizes the
responses of plasma LDL and apoB concentrations, alanine
aminotransferase (ALT) values, intrahepatic triglyceride
(IHTG) contents and timing of liver biopsy in patients
treated with mipomersen. Table 2 summarizes the histologic
findings for each biopsy.Table 1 Biochemical responses and timing of liver biopsy in mipom
Case Rx (wk)
Max ALT
(wk)
Biopsy
week
Baseline LDL-C
(mg/dL)
Final LDL-C
(mg/dL)
1* 25 126 (36) 22 209 85
2* 26 160 (28) 21 167 56
3 35 103 (28) 34 94 23
4 52 126 (52) 47 121 52
5 100 94 (43) 73 264 124
6 159 79 (129*) 159† 562 376
7 60 200 (26) 56 195 NA
apoB, apolipoprotein B; IHTG, intrahepatic triglyceride; LDL-C, low-density
enrolled in a blinded study.
*Biopsy previously reported, but reanalyzed as part of this study.4
†This patient was treated with mipomersen for 104 weeks, followed by a 2Results
Case 1
A 59-year-old white male with coronary artery disease,
as evidenced by a myocardial infarction requiring percuta-
neous coronary intervention (PCI), and hypercholesterole-
mia, hypertension, and impaired fasting glucose was
randomized to receive 200 mg mipomersen weekly as
part of a 26-week double-blind, placebo-controlled phase 2
study.4 He was intolerant of statins because of myalgias and
was not receiving other lipid-lowering medications. The
patient had a long history of alcohol abuse and consumed
the maximum allowable intake of 12 drinks per week
throughout the study. His ALT was 37 U/L at baseline. In
response to an increase in IHTG content from 17.8% in
week 4 to 34.7% as determined by MRS during week
18,4 liver biopsy was performed at treatment week 22. As
shown in Figure 1, this revealed severe macrosteatosis
without lobular inflammation or fibrosis. At week 25, treat-
ment was permanently discontinued because of moderate
flu-like symptoms, which were attributed to the study
drug. The IHTG contents at weeks 26 and 52 were 42.0%
and 28.4%, respectively. At the time mipomersen was
discontinued, the patient’s ALT was 80 U/L, peaked at
126 U/L at week 36, and fell to 57 U/L (,1.5 upper limit
of normal [ULN]) at week 58.
Case 2
A 58-year-old white male with hypercholesterolemia
and coronary artery disease, as evidenced by a myocardial
infarction requiring PCI, was randomized to receive
200 mg mipomersen weekly as part of a 26-week double-
blind, placebo-controlled phase 2 study.4 He was intolerant
of statins because of myalgias and was instead receiving
colesevelam 625 mg daily. This patient consumed 10ersen-treated patients
Baseline apoB
(mg/dL)
Final apoB
(mg/dL)
Initial IHTG
% (wk)
IHTG on
treatment % (wk)
146 77 17.8 (4) 34.7 (18)
126 40 23.7 (11) 47.3 (30)
27.0 (50)
90 28 (28) 2.5 (1) 33.9 (28)
31 (36) 36.1 (36)
113 46 2 (1) 23.6 (44)
171 92 36.7 (52) 35.8 (100)
349 221 ,1 (39) ,1 (156)
126 NA 5.6 NA
lipoprotein cholesterol; NA, not available because the patient remains
8 week hiatus, and then treated for 55 more weeks.
Table 2 Summary of histologic findings
Case
Portal*
inflammation
Lobular
inflammation
Sinusoidal
lymphocytosis
Hepatocyte
necrosis Steatosis Fibrosis
Kupffer cell
hyperplasia
Regenerative
changes
1 1 0 1 1 3 0 Present Present
2 1 1 1 2 3 0 Present Present
3 1 0 0 1 3 0 Present Present
4 0 0 0 1 3 0 Present Present
5 1 0 0 0 3 0 Present Present
6 0 0 0 0 1 0 Absent Present
7 0 1 2 1 1 0 Present Present
*Histologic features were graded on a semiquantitative integer scale of 0 (none present) to 4 (maximally present).
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normal at baseline and increased progressively during treat-
ment, peaking at 160 U/L at week 28. In response to anFigure 1 Severe steatosis without inflammation or fibrosis in a
patient treated with mipomersen for 22 weeks (case 1). Low-
(A) and high-power (B) image of a patient treated with mipo-
mersen. At low power (A), the liver shows marked, predominantly
macrovesicular, steatosis in zone 3 and zone 2 of the liver lobules
(asterisk), and a mild patchy mononuclear infiltrate in the portal
tract (arrow). At high power (B), the liver parenchyma shows mac-
rovesicular steatosis (arrow) and a few scattered mononuclear
cells in the liver sinusoids (arrowhead), but an absence of liver
cell necrosis or steatohepatitis.ALT increase to .2 ULN at week 11, an MRI was per-
formed and showed an IHTG content of 23.7%. A liver bi-
opsy was performed at treatment week 21 and revealed
severe macrosteatosis with mild focal lobular inflammation
and no fibrosis.4 The patient completed all 26 weeks of
mipomersen. The IHTG content peaked at 47.3% at week
30 and decreased to 27.0% at week 50. The patient’s
ALT was 125 U/L at week 24, 160 U/L at week 28, and
54 U/L (,1.5 ULN) at week 50.
Case 3
A 62-year-old white female with heterozygous FH,
hypertension, and type 2 diabetes was randomized to
receive mipomersen 200 mg weekly as part of a 13-week
double-blind, placebo-controlled study, followed by
weekly open-label mipomersen.3 She received atorvasta-
tin 10 mg daily concurrently and consumed 1 alcoholic
drink per week during the study. Her ALT was 10 U/L
at the time of enrollment. Liver biopsy was performed
at treatment week 34 to evaluate an increase in IHTG con-
tent by MRS from 2.5% at baseline to 33.9% at week 28,
and an elevated ALT, which peaked at 103 U/L at week
28. The biopsy revealed severe macrosteatosis without
lobular inflammation or fibrosis. Mipomersen treatment
was nevertheless discontinued at week 35 because of con-
cerns of possible drug-related liver injury. During the
posttreatment follow-up period, both her IHTG content
and ALT progressively declined, reaching 18.4% and 24
U/L, respectively, at posttreatment week 20. Her IHTG
content further declined to 6.0% at posttreatment
week 50.
Case 4
A 64-year-old white female with heterozygous FH and
type 2 diabetes was randomized to receive mipomersen
200 mg weekly as part of a 13-week double-blind, placebo-
controlled study, followed by weekly open-label mipo-
mersen to evaluate the safety and efficacy of extended
dosing.3 She received simvastatin 20 mg daily concurrently
and consumed 3 alcoholic drinks per week during the study.
Because of increasing IHTG content by MRS (2.0% at
Figure 2 Mild macrovesicular and focal microvesicular steato-
sis with focal mild portal and lobular inflammation and no fibrosis
in a patient treated with mipomersen for 56 weeks (case 7). Liver
biopsy in 1 patient in this study treated with mipomersen showed
only a mild degree of macrovesicular steatosis (long arrows).
Instead, the findings were prominent sinusoidal mononuclear
inflammation (arrowhead), spotty hepatocyte necrosis (O), regen-
erative changes (binucleated cells, prominent nucleoli, anisonu-
cleosis), and Kupffer cell hyperplasia (short arrows). Also note
the mild focal degree of mononuclear inflammation in the portal
tract (asterisk).
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tively) and a rise in ALT (from 23 IU/L at screening to
99 U/L at week 44), liver biopsy was performed at treat-
ment week 47. This revealed severe macrosteatosis, but
without evidence of lobular inflammation or fibrosis. The
patient completed the treatment period (52 weeks). During
the posttreatment follow-up period, both her IHTG content
and ALT improved, reaching 15.7% and 53 U/L, respec-
tively, at posttreatment week 12. Her ALT fell to 28 IU/L
at posttreatment week 19.
Case 5
A 60-year-old white male with severe heterozygous FH
leading to premature coronary artery disease and PCI was
randomized to receive mipomersen 200 mg weekly for
26 weeks, and was enrolled into an open-label treatment
extension study of weekly mipomersen to evaluate the
safety and efficacy of extended dosing.7,8 He was concur-
rently receiving rosuvastatin 20 mg daily, ezetimibe
10 mg daily, fenofibrate 160 mg daily, and fish oil. This
patient did not consume any alcohol during the study. Liver
biopsy was performed at treatment week 74 for evaluation
of abdominal pain and ultrasound finding of hepatic steato-
sis. The biopsy showed severe macrosteatosis without
lobular inflammation or fibrosis. His ALT had peaked at
94 IU/L at treatment week 43 but was normal at the time
of the biopsy. He continued to receive mipomersen for
nearly 2 years.
Case 6
A 48-year-old white female with homozygous FH was
randomized to receive mipomersen at a reduced dose of
160 mg weekly because of a body weight ,50 kg during a
26-week double-blind, placebo-controlled phase 3 trial of
mipomersen, and then enrolled into an open-label treatment
extension study of weekly mipomersen at 200 mg per
week.5,8 She did not consume any alcohol during the study.
She was concurrently receiving atorvastatin 80 mg daily
and ezetimibe 10 mg daily. Her IHTG content by MRI
was normal at baseline and throughout the study, and
ALT remained ,2! ULN. Liver biopsy was performed
because of prolonged (159 weeks) exposure to mipomersen
and revealed mild steatosis without lobular inflammation or
fibrosis.
Case 7
A 45-year-old white male with heterozygous FH was
randomized to receive mipomersen during a phase 3,
double-blind, placebo-controlled study followed by an
open-label continuation period to assess the safety and
efficacy of 2 regimens of mipomersen (clinicaltrials.gov/
show/NCT01475825). He was receiving simvastatin
40 mg daily and niacin 1000 mg daily at study initiation.
This patient consumed 1 alcoholic drink daily throughoutthe study. Liver biopsy was performed at treatment week
56 for evaluation of persistently elevated ALT ($3!
ULN) for more than 3 months and ultrasound showing fatty
liver. As shown in Figure 2, this revealed mild macrovesic-
ular and focal microvesicular steatosis with focal lobular
inflammation and no fibrosis. Of note, the patient had opted
not to take mipomersen during weeks 41-47 and had taken
it every other week during weeks 51-59, without informing
the investigators. Treatment was stopped at the study
conclusion (week 60). His ALT peaked at 200 IU/L at treat-
ment week 26 but decreased to 68 U/L at the time of bi-
opsy. The results of all lipid studies and MRIs remain
blinded as part of this ongoing study.Discussion
Because increasing plasma clearance of LDL by statin
therapy is not feasible in homozygous FH patients who lack
functional LDL receptors and is often incomplete in
heterozygotes, therapies with the potential to reduce the
rate of VLDL secretion represent an attractive alternative
for reducing plasma concentrations of pro-atherogenic
lipoproteins. This is because LDL particles are formed in
the plasma primarily by the intravascular catabolism of
apolipoprotein B-100–containing VLDL particles, which
are secreted by the liver and transport triglyceride mole-
cules to muscle and adipose tissue. VLDL is assembled
within hepatocytes when apoB-100 is cotranslationally
lipidated with triglycerides by the action of microsomal
triglyceride transfer protein. After secretion into plasma by
610 Journal of Clinical Lipidology, Vol 8, No 6, December 2014the liver, triglyceride-rich VLDL is remodeled into LDL,
principally by the activity of lipoprotein lipase in the
capillary endothelia of muscle and adipose tissue as well as
hepatic lipase on the surface of hepatocytes.
The secretion of VLDL particles appears to be effec-
tively inhibited by 2 pharmacologic approaches, each of
which has led to Food and Drug Administration–approved
therapies for homozygous FH.9 Whereas mipomersen is an
antisense oligonucleotide that reduces apoB-100 produc-
tion, lomitapide is a small molecule inhibitor of micro-
somal triglyceride transfer protein. Both medications
reduce LDL substantially, but both also lead to an increase
in IHTG contents in many patients who receive these ther-
apeutic agents, presumably by reducing the export of
triglycerides from the liver via VLDL. Elevations in trans-
aminase values have been observed with both mipo-
mersen2,5-7 and lomitapide10,11 and assessments of hepatic
steatosis have been made based on MRS and MRI. Be-
cause these noninvasive techniques only assess the pre-
sence and quantity of fat, it remains unclear whether the
mechanism-based accumulation of hepatic triglycerides
associated with therapies that reduce VLDL secretion leads
to simple steatosis or steatohepatitis (ie, steatosis associated
with inflammation and fibrosis).
To address this issue, we evaluated liver histopathology
in 7 patients treated with mipomersen (for 23-159 weeks)
who underwent liver biopsy. In 6 individuals (cases 1-5 and
7), biopsies were performed because of concerns about
elevations in transaminases and liver triglyceride concen-
trations. In 1 instance (case 6), a liver biopsy was
performed because the patient had been treated for an
extended period. In all but 2 patients (cases 2 and 7), the
histopathologic findings were characterized by steatosis,
without inflammation or fibrosis. In case 6, where the
biopsy was performed after 159 weeks of therapy, mild
steatosis without inflammation or fibrosis was observed.
The average maximal ALT (mean 6 standard error of the
mean) was 3.0 6 0.4 ULN. The average increase in IHTG
content was 15.8 6 5.6. Flu-like symptoms and injection
site reactions each occurred in 4 cases.
These results suggest that steatosis induced by mipo-
mersen therapy is not associated with liver cell injury. The
same features are observed for the majority of patients with
non-alcoholic fatty liver disease (NAFLD) in whom the
liver histopathology is characterized by simple steatosis
(non-alcoholic fatty liver, NAFL), and the clinical course is
benign. NASH develops in a minority of NAFLD patients,
and is characterized by lobular inflammation, fibrosis, and
ballooning degeneration of hepatocytes as well as progres-
sive disease that may culminate in cirrhosis. In this study,
only mild lobular inflammation was present in 2 patients
(cases 2 and 7). NASH is more commonly associated with
certain metabolic risk factors, including obesity and type 2
diabetes.12 NAFLD is characterized by increased rates of
VLDL secretion, but these are insufficient to compensate
for increases in IHTG concentrations, which are attribut-
able to increased hepatic lipogenesis and uptake of plasmafree fatty acids.13 By contrast, the pathogenesis of hepatic
steatosis in familial hypobetalipoproteinemia (FHBL) is
more closely related to what occurs with mipomersen ther-
apy: FHBL is caused primarily by truncation mutations of
the apoB gene, which lead to decreased VLDL production,
leading to impaired export of triglycerides and hepatic stea-
tosis.14 Despite the presence of severe hepatic steatosis in
FHBL, fibrosis and cirrhosis have only rarely been
reported. Moreover, in a study that compared the liver find-
ings in patients with NAFLD and hepatitis C infection,
hepatic steatosis in FHBL was associated with a lower
grade of inflammation and a lower stage of fibrosis, and
insulin resistance was absent.15 These findings support the
concept that hepatic fat accumulation associated with
apoB inhibition may reflect a distinct metabolic condition
compared with NAFLD.15,16 Suggestive of hepatic adapta-
tion to reduced triglyceride secretion, liver enzymes and
IHTG contents measured by MRI have tended to decrease
and stabilize after 1 year of mipomersen therapy.2,8
Our study has important limitations. Liver biopsies
were performed at the discretion of the treating physicians
at each study center, and only in a small minority of
patients who had increased liver fat on imaging or
elevated serum transaminases. Baseline liver biopsies
were not performed before treatment, and most biopsies
were performed after a relatively short duration of
exposure (,2 years). It is possible that patients who had
early discontinuation of mipomersen resulting from sig-
nificant ALT elevations but without liver biopsy, also had
more severe liver injury. Although steatohepatitis did not
develop in the 2 patients who received mipomersen for at
least 2 years, the effect of long-duration therapy on the
liver was not determined in our small sample. It is
possible that steatohepatitis from inhibition of VLDL
secretion could require substantially more time to
develop.17Conclusion
Our findings suggest that in the majority of cases,
steatosis without inflammation results from apoB inhibi-
tion, similar to what is generally observed in patients with
FHBL.
References
1. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an
apolipoprotein B synthesis inhibitor, on low-density lipoprotein
cholesterol in patients with familial hypercholesterolemia. Am J
Cardiol. 2010;105:1413–1419.
2. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M.
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces athero-
genic lipoproteins in patients with severe hypercholesterolemia at high
cardiovascular risk: a randomized, double-blind, placebo-controlled
trial. J Am Coll Cardiol. 2013;62:2178–2184.
3. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B
synthesis inhibition on liver triglyceride content in patients with famil-
ial hypercholesterolemia. J Lipid Res. 2010;51:1057–1062.
Hashemi et al Liver histology during Mipomersen therapy 6114. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipopro-
tein B synthesis inhibitor, lowers low-density lipoprotein cholesterol
in high-risk statin-intolerant patients: a randomized, double-blind,
placebo-controlled trial. Eur Heart J. 2012;33:1142–1149.
5. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B
synthesis inhibitor, for lowering ofLDLcholesterol concentrations in pa-
tients with homozygous familial hypercholesterolaemia: a randomised,
double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
6. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhi-
bition with mipomersen in heterozygous familial hypercholesterole-
mia: results of a randomized, double-blind, placebo-controlled trial
to assess efficacy and safety as add-on therapy in patients with
coronary artery disease. Circulation. 2012;126:2283–2292.
7. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-
controlled trial of mipomersen in patients with severe hypercholester-
olemia receiving maximally tolerated lipid-lowering therapy. PLoS
One. 2012;7:e49006.
8. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mi-
pomersen in patients with familial hypercholesterolaemia: 2-year interim
results of anopen-label extension. EurHeart J. 2013 [Epub aheadof print].
9. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class
drugs for reducing low-density lipoprotein cholesterol in patients with
homozygous familial hypercholesterolemia. Circulation. 2014;129:
1022–1032.10. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal
triglyceride transfer protein in familial hypercholesterolemia. N Engl
J Med. 2007;356:148–156.
11. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety
of a microsomal triglyceride transfer protein inhibitor in patients with
homozygous familial hypercholesterolaemia: a single-arm, open-label,
phase 3 study. Lancet. 2013;381:40–46.
12. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver
disease. Clin Liver Dis. 2012;16:397–419.
13. Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and
nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33:380–388.
14. Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial
hypobetalipoproteinemia: roles of the APOB defects, intra-
abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004;
45:941–947.
15. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and
insulin resistance: does etiology make a difference? J Hepatol.
2006;44:190–196.
16. Visser ME, Lammers NM, Nederveen AJ, et al. Hepatic steatosis does
not cause insulin resistance in people with familial hypobetalipopro-
teinaemia. Diabetologia. 2011;54:2113–2121.
17. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with
pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern
Med. 2014;174:443–447.
